safety – Asian Pacific Journal of Allergy and Immunology

August 9, 2026

A multicenter study of crisaborole use in pediatric patients with atopic dermatitis in real-world setting in Thailand

Increasing evidence supports the efficacy of crisaborole in atopic dermatitis (AD). Ethnic differences in AD endotypes may influence treatment outcomes, while data in Southeast Asian children remain limited.

AD, crisaborole, efficacy, safety, Thai children

April 23, 2023

Efficacy and safety of low- and high-dose slow oral egg immunotherapy for hen’s egg allergy: Single-center non-inferiority randomized trial

Low-dose oral immunotherapy (OIT) is a safe treatment for hen’s egg allergy; however, comparison of its therapeutic effects with those of high-dose OIT has not been reported.

efficacy, Egg allergy, oral immunotherapy, safety

April 23, 2023

Safety of House Dust Mite Subcutaneous Immunotherapy with a rush and cluster combination protocol in the build-up phase

Conventional and cluster subcutaneous immunotherapy (SCIT) are effective but may be time-consuming. Rush SCIT may offer a more convenient treatment option to patients and be of shorter duration; however, it is also associated with a higher incidence of systemic adverse reactions. Therefore, a combination of protocols between rush and cluster SCIT could have a superior risk-benefit ratio.

allergen, house dust mites, Immunotherapy, risk factor, safety

January 2, 2023

COVID-19 Vaccine Allergy Safety Track (VAS-Track) pathway: real-world outcomes on vaccination rates and antibody protection

Misdiagnosed vaccine-related “allergies” lead to unnecessary vaccine deferrals and incomplete vaccinations, leaving patients unprotected against COVID-19. To overcome limitations and queues for Allergist assessment, the “VAS-Track” pathway was developed to evaluate patients via a multi-disciplinary triage model including nurses, non-specialists, and Allergists.

Allergy, antibody, COVID-19, safety, vaccine

December 20, 2021

Biological therapy in Psoriasis: An emphasis on its dermatologic adverse events

Review Article Biological therapy in Psoriasis: An emphasis on its dermatologic adverse events Pasita Palakornkitti,1 Kulsupa Nimmannitya,1 Ploysyne Rattanakaemakorn1 1 Division of Dermatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Abstract Objective: To report...

adalimumab, ADR, AE, bimekizumab, brodalumab, Etanercept, guselkumab, Infliximab, ixekizumab, risankizumab, safety, secukinumab, side effect, skin (cutaneous), tildrakizumab, ustekinumab

January 30, 2021

Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data

Omalizumab is a safe and effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU) but is insufficient in one-third of patients. For serious cases in which omalizumab is ineffective, cyclosporine or methotrexate may be preferred. Most drug trials in CSU have focused on omalizumab or cyclosporine monotherapy.

chronic spontaneous urticaria, cyclosporine, efficacy, methotrexate, Omalizumab, safety, treatment

July 13, 2020

Efficacy, patients’ perception, and cost of medication in allergic rhinitis with subcutaneous immunotherapy

Allergic rhinitis (AR) is the allergic inflammation of nasal mucosa. Treatment of AR includes pharmacotherapy and allergen immunotherapy. Subcutaneous immunotherapy (SCIT) is indicated in inadequate disease control, patient’s preference, or impossible allergen avoidance. SCIT is an effective treatment but its cost is comparatively high. Efficacy, patient perception, and cost of medication are rarely explored in Asia.

cost-benefit, efficacy, Immunotherapy, perception, safety

May 18, 2020

Effect of inhaled corticosteroids on bone mineral density in patients with asthma

Inhaled corticosteroids (ICS) are a safe treatment for asthma. However, at higher doses, ICS use has been reported to inhibit adrenocortical function.

Asthma, Bone mineral density, Inhaled corticosteroids (ICS), Osteoporosis, safety